Cargando…

Unexpected responses to EGFR inhibition in NSCLC

The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identifies a distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demonstrated that EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are superior to stand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stella, Giulia M., Valizia, Claudio, Zorzetto, Michele, Inghilleri, Simona, Valentini, Adele, Dore, Roberto, Colombo, Sara, Valentino, Francesco, Orlandoni, Giulio, Morbini, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681892/ https://www.ncbi.nlm.nih.gov/pubmed/26744648 http://dx.doi.org/10.1016/j.rmcr.2015.06.006

Ejemplares similares

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
por: Stella, Giulia M., et al.
Publicado: (2014)

Factors Influencing Oxidative Imbalance in Pulmonary Fibrosis: An Immunohistochemical Study
por: Inghilleri, Simona, et al.
Publicado: (2011)

5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin
por: Bosio, Matteo, et al.
Publicado: (2018)

Synchronous Lung Cancers: When Same Histological Types Feature Different Molecular Profiles and Response Phenotypes
por: Stella, Giulia M, et al.
Publicado: (2011)

Erratum to “Factors Influencing Oxidative Imbalance in Pulmonary Fibrosis: An Immunohistochemical Study”
por: Inghilleri, S., et al.
Publicado: (2011)

miRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p
por: Bozzini, Sara, et al.
Publicado: (2021)

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Case Report: All That Glisters Is Not(*) Cancer
por: Tirelli, Claudio, et al.
Publicado: (2020)

A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant
por: Campo, Ilaria, et al.
Publicado: (2014)

CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis
por: Tirelli, Claudio, et al.
Publicado: (2020)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study
por: Di Carlo, Stefano, et al.
Publicado: (2016)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Unexpected insights for anti-EGFR cancer therapy
por: Depeille, Philippe, et al.
Publicado: (2015)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Classical and Unexpected Effects of Ultra-Micronized PEA in Neuromuscular Function
por: Cifelli, Pierangelo, et al.
Publicado: (2022)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
por: Santaniello, Antonio, et al.
Publicado: (2019)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

The growth of non-solid neoplastic lung nodules is associated with low PD L1 expression, irrespective of sampling technique
por: Bortolotto, Chandra, et al.
Publicado: (2020)

Current Approaches in NSCLC Targeting K-RAS and EGFR
por: Aran, Veronica, et al.
Publicado: (2019)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
por: Boukansa, Sara, et al.
Publicado: (2023)

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
por: Yan, Dan
Publicado: (2023)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway
por: Taverna, Simona, et al.
Publicado: (2017)

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c7inrmpa70dd1vbks4h09qd3ct